Benign Prostatic Hyperplasia Prostate Treatment Market Size

  • Report ID: 4218
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Benign Prostatic Hyperplasia Prostate Treatment Market Size

Benign Prostatic Hyperplasia Prostate Treatment Market size was over USD 7.86 billion in 2024 and is likely to cross USD 16.09 billion by the end of 2037, growing at more than 5.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of benign prostatic hyperplasia prostate treatment is estimated at USD 8.22 billion.

The growth of the market can primarily be ascribed to the growing rate of BPH surgical treatment since it can cost one’s life. Moreover, it is a disorder that is generally observed in men around the world, it is anticipated to increase the market’s growth. For instance, nearly 200,000 prostatectomy procedures are carried every year for benign diseases in the United States.

Global benign prostatic hyperplasia (BPH) prostate treatment market trends such as, the higher prevalence of benign prostatic hyperplasia (BPH) and rising awareness of the disease are estimated to hike the growth of the market over the forecast period. Moreover, benign prostatic hyperplasia has been accepted as an increasing health problem among aged men, and it is predicted to increase the market’s growth in the upcoming years.  For instance, benign prostatic hyperplasia becomes more prevalent in men after the age of 40 with a prevalence rate of approximately 10% to 65% across the globe.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4218
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of benign prostatic hyperplasia prostate treatment is estimated at USD 8.22 billion.

The benign prostatic hyperplasia prostate treatment market size was over USD 7.86 billion in 2024 and is likely to cross USD 16.09 billion by the end of 2037, growing at more than 5.8% CAGR during the forecast period i.e., between 2025-2037. Higher prevalence of benign prostatic hyperplasia (BPH), developing medical technology across the globe, increasing healthcare expenditure per capita, and spiking cases of urinary tract infection will drive the market growth.

North America is projected to account for majority industry share by 2037, ascribed to rising geriatric population, an increasing unhealthy lifestyle, and a higher prevalence of benign prostatic hyperplasia.

The major players in the market include Pfizer Inc., Cardinal Health Inc., NxThera, Inc., Veru, Inc., Teleflex Incorporated, Eli Lily & Company, Sanofi S.A., GSK plc, Mylan N.V., AbbVie Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample